Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reqorsa + Erlotinib in Stage IV NSCLC
NCT01455389Phase 2Terminated
- Sponsor
- Genprex, Inc.
- Start
- Feb 2014
- Primary completion
- Oct 2016
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
A Phase 2 trial of quaratusugene ozeplasmid in non-small cell lung cancer (NSCLC), sponsored by Genprex, Inc.. Started Feb 2014; status: terminated.
02
Drugs
quaratusugene ozeplasmid
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01455389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01455389.